ID   B-CPAP
AC   CVCL_0153
SY   BC-PAP; BCPAP
DR   BTO; BTO:0004736
DR   CLO; CLO_0001906
DR   MCCL; MCC:0000045
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471001
DR   BioSample; SAMN10989558
DR   cancercelllines; CVCL_0153
DR   CCRID; 3101HUMSCSP543
DR   Cell_Model_Passport; SIDM00992
DR   ChEMBL-Cells; CHEMBL3308356
DR   ChEMBL-Targets; CHEMBL1075394
DR   CLS; 305081
DR   Cosmic; 755292
DR   Cosmic; 849970
DR   Cosmic; 924104
DR   Cosmic; 928836
DR   Cosmic; 931241
DR   Cosmic; 1084279
DR   Cosmic; 1162847
DR   Cosmic; 1237447
DR   Cosmic; 1239965
DR   Cosmic; 1280047
DR   Cosmic; 1507369
DR   Cosmic; 1533552
DR   Cosmic; 1536122
DR   Cosmic; 1889007
DR   Cosmic; 2036692
DR   Cosmic; 2054086
DR   Cosmic; 2319847
DR   Cosmic; 2613253
DR   Cosmic; 2791089
DR   Cosmic-CLP; 924104
DR   DepMap; ACH-000456
DR   DSMZ; ACC-273
DR   DSMZCellDive; ACC-273
DR   EGA; EGAS00001000978
DR   GDSC; 924104
DR   GEO; GSM886875
DR   GEO; GSM887940
DR   GEO; GSM1669612
DR   IARC_TP53; 25011
DR   LiGeA; CCLE_362
DR   LINCS_LDP; LCL-1687
DR   NCBI_Iran; C596
DR   PharmacoDB; BCPAP_82_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0153
DR   PubChem_Cell_line; CVCL_0153
DR   Wikidata; Q54752132
RX   PubMed=1297527;
RX   PubMed=8156527;
RX   PubMed=11439348;
RX   PubMed=14522906;
RX   PubMed=15172756;
RX   PubMed=17725429;
RX   PubMed=17804723;
RX   PubMed=18713817;
RX   PubMed=19087340;
RX   PubMed=20164919;
RX   PubMed=21868764;
RX   PubMed=22087789;
RX   PubMed=22460905;
RX   PubMed=23162534;
RX   PubMed=23833040;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28775782;
RX   PubMed=30737244;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=32666385;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: ~30 hours (DSMZ=ACC-273).
CC   HLA typing: A*02:01,33:01; B*18:01,35:01; C*04:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23162534; PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Homozygous (PubMed=14522906; PubMed=23162534; PubMed=30737244; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.56%; Native American=1.26%; East Asian, North=0.45%; East Asian, South=1.09%; South Asian=1.92%; European, North=43.75%; European, South=50.97% (PubMed=30894373).
CC   Caution: Originally classified a thyroid gland papillary carcinoma (PTC) but is now considered to be a poorly differentiated thyroid gland carcinoma (PDTC) (PubMed=23162534).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): Cosmic-CLP; DSMZ; PubMed=18713817; PubMed=21868764; PubMed=25877200; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 12
ST   D16S539: 11,12
ST   D18S51: 13,17
ST   D19S433: 13.2,15 (PubMed=25877200)
ST   D19S433: 14,15 (DSMZ)
ST   D21S11: 30 (DSMZ)
ST   D21S11: 30,31.2 (PubMed=18713817; PubMed=25877200; PubMed=30737244)
ST   D2S1338: 18
ST   D3S1358: 16,17
ST   D5S818: 10,11
ST   D7S820: 10
ST   D8S1179: 12,13
ST   FGA: 20,23
ST   Penta D: 10,11
ST   Penta E: 5,12 (DSMZ)
ST   Penta E: 5,12,17 (PubMed=25877200)
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C6040; Poorly differentiated thyroid gland carcinoma
DI   ORDO; Orphanet_100088; Thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   76Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   PubMed=1297527;
RA   Paulin C., Fabien N., Fusco A., Pages M.-P., Patricot M.-C., Bornet H.,
RA   Dubois P.-M.;
RT   "Description of a cell line established from a human thyroid papillary
RT   carcinoma and synthesizing human chorionic gonadotropin hormone.";
RL   C. R. Acad. Sci. III, Sci. Vie 315:493-498(1992).
//
RX   PubMed=8156527; DOI=10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M;
RA   Fabien N., Fusco A., Santoro M., Barbier Y., Dubois P.-M., Paulin C.;
RT   "Description of a human papillary thyroid carcinoma cell line.
RT   Morphologic study and expression of tumoral markers.";
RL   Cancer 73:2206-2212(1994).
//
RX   PubMed=11439348; DOI=10.1038/sj.onc.1204531;
RA   Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.;
RT   "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile
RT   response to hepatocyte growth factor.";
RL   Oncogene 20:3845-3856(2001).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=15172756; DOI=10.1016/j.cancergencyto.2003.09.023;
RA   Dettori T., Frau D.V., Garcia J.L., Pierantoni G.M., Lee C.,
RA   Hernandez J.M., Fusco A., Morton C.C., Vanni R.;
RT   "Comprehensive conventional and molecular cytogenetic characterization
RT   of B-CPAP, a human papillary thyroid carcinoma-derived cell line.";
RL   Cancer Genet. Cytogenet. 151:171-177(2004).
//
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
//
RX   PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026;
RA   van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G.,
RA   Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.;
RT   "Human thyroid tumor cell lines derived from different tumor types
RT   present a common dedifferentiated phenotype.";
RL   Cancer Res. 67:8113-8120(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371.1-371.11(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=22087789; DOI=10.1186/1755-8166-4-26;
RA   Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.;
RT   "Centrosomal and mitotic abnormalities in cell lines derived from
RT   papillary thyroid cancer harboring specific gene alterations.";
RL   Mol. Cytogenet. 4:26.1-26.8(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23162534; DOI=10.3389/fendo.2012.00133;
RA   Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A.,
RA   van Staveren W.C.G., Maenhaut C.;
RT   "Thyroid cancer cell lines: an overview.";
RL   Front. Endocrinol. 3:133.1-133.9(2012).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28775782; DOI=10.7150/jca.18855;
RA   Caria P., Pillai R., Dettori T., Frau D.V., Zavattari P., Riva G.,
RA   Romano G., Pani F., Bentivegna A., Giovannoni R., Pagni F., Sogos V.,
RA   Vanni R.;
RT   "Thyrospheres from B-CPAP cell line with BRAF and TERT promoter
RT   mutations have different functional and molecular features than
RT   parental cells.";
RL   J. Cancer 8:1629-1639(2017).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//
RX   PubMed=32666385; DOI=10.1007/s12020-020-02417-y;
RA   Run L., Wang L.-P., Nong X.-T., Li N., Huang X., Xiao Y.;
RT   "Involvement of HMGB1 in vemurafenib resistance in thyroid cancer
RT   cells harboring BRAF (V600E) mutation by regulating excessive
RT   autophagy.";
RL   Endocrine 71:418-426(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//